xRead - September 2022

Wise et al.

Page 365

Author Manuscript Author Manuscript Author Manuscript Author Manuscript Study design Study groups Clinical endpoint Conclusion

Shah et al. 1208 2009 1b DBRCT 1 Olopatadine 2.66 mg BID; TNSS Both treatments superior to placebo; no difference between treatments; less bitter taste with olopatadine. van Bavel et al. 1209 2009 1b DBRCT 1 Azelastine 0.82 mg daily; 2 Placebo TNSS Azelastine superior to placebo. 2 Azelastine 0.56 mg BID; 3 Placebo

Meltzer et al. 1210 2008 1b DBRCT 1 Olopatadine 2.66 mg BID; 2 Azelastine 0.56 mg BID Sensory perception Olopatadine favored for taste, aftertaste, and likelihood of use. Pipkorn et al. 1211 2008 1b DBRCT 1 Olopatadine 0.1%, (dose not given); 2 Olopatadine 0.2% (dose not given); 3 Azelastine 0.1% (dose not given); 4 Placebo 4-item symptom score, nasal lavage Both olopatadine doses superior to placebo for reducing symptoms; higher concentration inhibits mast cell degranulation. Lumry et al. 1212 2007 1b DBRCT 1 Azelastine 0.28 mg daily; 2 Azelastine 0.28 mg BID; 3 Placebo

TNSS Azelastine both doses superior to placebo.

TNSS Azelastine superior to mometasone and placebo. TNSS, patient satisfaction

Olopatadine superior to placebo and mometasone in reducing symptoms; faster onset for olopatadine.

Berger et al. 1215 2006 1b DBRCT 1 Azelastine 0.56 mg BID; TNSS, RQLQ Azelastine superior for sneezing and nasal congestion; azelastine superior for QOL. Hampel et al. 1216 2006 1b DBRCT 1 Olopatadine 2.66 mg BID; 2 Olopatadine 1.77 mg BID; 3 Placebo Total Symptom Score, RQLQ 2 Cetirizine 10-mg tablet daily

Olopatadine (both doses) superior to placebo in majority of domains for QOL improvement.

Patel et al. 1213 2007 1b DBRCT 1 Azelastine 0.56 mg daily;

2 Mometasone furoate 0.2 mg spray QD; 3 Placebo

Patel et al. 1214 2007 1b DBRCT 1 Olopatadine 2.66 mg daily;

2 Mometasone furoate 0.2 mg spray QD; 3 Placebo

Study Year LOE

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.